Georgian medical news · 2025
IMMUNOMODULATORS IN THE TREATMENT OF ATHEROSCLEROSIS AND OTHER CHRONIC HEART DISEASES: PROSPECTS AND RISKS.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tyravska Y, Maltsev D, Moyseyenko V, Reshetylo V, Yakymenko V
Аннотация
INTRODUCTION: Atherosclerotic cardiovascular diseases remain the leading cause of mortality worldwide, with chronic inflammation driving progression despite traditional lipid-lowering and antiplatelet therapy, leaving substantial residual cardiovascular risk. This study aimed to systematically analyze immunomodulator efficacy and safety in treating atherosclerosis and chronic cardiac diseases, determining therapeutic potential and associated risks.
METHODS: A systematic search of Scopus, Web of Science, PubMed, Embase, and the Cochrane Library identified 264 records. After removing 134 duplicates and screening 130 unique records, 74 studies (20 randomized controlled trials, 16 systematic reviews/meta-analyses, 22 prospective cohort studies, 9 retrospective analyses, and 7 experimental studies) were selected that met the inclusion criteria and were included in the qualitative synthesis according to PRISMA 2020.
RESULTS: Three main immunomodulator categories demonstrated cardiovascular efficacy: interleukin-1β inhibitors (canakinumab reduced events by 15%), small anti-inflammatory molecules (colchicine achieved 23-31% risk reduction), and interleukin-6 receptor antagonists (tocilizumab reduced infarct size by 12.4%). However, biological agents showed increased infectious complications, with canakinumab demonstrating statistically significant fatal infection increase. Immunomodulatory therapy represents transformative advancement targeting inflammatory mechanisms beyond lipid reduction. Colchicine emerged as priority drug for clinical implementation given optimal efficacy-cost ratio and favorable safety profile, while biologics face economic barriers exceeding $70,000 annually.
CONCLUSIONS: Long-term monitoring of immunosuppressive therapy safety profiles, particularly regarding infectious complications and oncological risks, remains critically important for future large-scale studies requiring decade-long surveillance in diverse populations.
METHODS: A systematic search of Scopus, Web of Science, PubMed, Embase, and the Cochrane Library identified 264 records. After removing 134 duplicates and screening 130 unique records, 74 studies (20 randomized controlled trials, 16 systematic reviews/meta-analyses, 22 prospective cohort studies, 9 retrospective analyses, and 7 experimental studies) were selected that met the inclusion criteria and were included in the qualitative synthesis according to PRISMA 2020.
RESULTS: Three main immunomodulator categories demonstrated cardiovascular efficacy: interleukin-1β inhibitors (canakinumab reduced events by 15%), small anti-inflammatory molecules (colchicine achieved 23-31% risk reduction), and interleukin-6 receptor antagonists (tocilizumab reduced infarct size by 12.4%). However, biological agents showed increased infectious complications, with canakinumab demonstrating statistically significant fatal infection increase. Immunomodulatory therapy represents transformative advancement targeting inflammatory mechanisms beyond lipid reduction. Colchicine emerged as priority drug for clinical implementation given optimal efficacy-cost ratio and favorable safety profile, while biologics face economic barriers exceeding $70,000 annually.
CONCLUSIONS: Long-term monitoring of immunosuppressive therapy safety profiles, particularly regarding infectious complications and oncological risks, remains critically important for future large-scale studies requiring decade-long surveillance in diverse populations.